rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two scenarios were considered, one in all confirmed patients with T790M-positive disease (scenario 1) and the other in all patients whose disease progressed after epidermal growth factor receptor tyrosine kinase inhibitor therapy, which consisted of patients with T790M-positive or T790M-negative NSCLC (scenario 2).
|
31607559 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the therapeutic strategy for overcoming acquired resistance to EGFR-TKIs in NSCLC patients without T790M remains to be definitively determined.
|
30993382 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our study provides a ctDNA validation for the purpose of T790M testing in EGFR mutant NSCLC.
|
31280508 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Olmutinib showed effective clinical activity with a manageable safety profile, indicating therapeutic potential for T790M-positive NSCLC patients who have failed ≥ 1 previous line of EGFR-TKI therapy.
|
31447004 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, TAS-121 displayed antitumor activity in SW48 (<i>EGFR</i> G719S) and NCI-H1975 (<i>EGFR</i> L858R/T790M) xenograft models, and achieved an objective response in patients with NSCLC with <i>EGFR</i> mutations including G719A mutation.
|
30872380 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib is a promising therapeutic option for patients with advanced non-small-cell lung cancer (NSCLC) in second-line or first-line treatment because of its applications in selectively inhibiting EGFR T790M and EGFR-tyrosine kinase inhibitor sensitizing mutations.
|
31562701 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We retrospectively analyzed 50 pre-treated EGFR T790M-positive NSCLC patients treated with osimertinib at seven Swiss centers.
|
30885336 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (<i>EGFR</i>) mutation testing (e.g., for T790M mutations), and the subsequent administration of third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).
|
31124335 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with centrally confirmed, T790M mutation-positive, advanced non-small cell lung cancer received osimertinib 80 mg once daily until disease progression or study discontinuation.
|
30512189 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is active against EGFR-mutant non-small cell lung cancer (NSCLC) resistant to first-/second-generation EGFR-TKIs with the T790M mutation.
|
30809659 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To identify the prevalence of EGFR T790M mutations in predominantly Caucasian patients with stage IV EGFR mutation-positive NSCLC who progressed on afatinib, and to investigate the subsequent response to osimertinib.
|
30539501 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We hypothesized that treatment with cabozantinib plus erlotinib in <i>EGFR</i> mutation-positive NSCLC following progression on EGFR TKI therapy may allow tumors to overcome this resistance or restore sensitivity to therapy regardless of T790M status.
|
30915273 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
An MR was detected in 15% of NSCLC patients with T790M.
|
30735003 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790M negative NSCLC patients.
|
31138260 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study was to assess the differential clinical outcomes of osimertinib therapy in NSCLC patients with T790M according to the type of activating <i>EGFR</i> mutation, ie, exon 19 deletion or L858R point </span>mutation.
|
31213907 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tag-based NGS represents an accurate and sensitive tool in a clinical setting for non-invasive assessment and monitoring of T790M variant in NSCLC patients.
|
31029076 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations.
|
31289574 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Conclusion In pretreated patients with T790M-mutated advanced NSCLC, the efficacy of osimertinib appears similar in real-world setting to that of clinical trials.
|
30642559 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Fifty-six distinct uncommon <i>EGFR</i> mutations other than L858R, exon19del, exon20ins, or T790M were identified in 18.9% of patients with <i>EGFR</i>-mutant NSCLC.
|
30902917 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We reviewed the medical records of consecutive patients with advanced NSCLC harboring EGFR-activating mutations and secondary T790M, who had undergone osimertinib re-administration to treat acquired resistance.
|
31097094 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
KEY POINTS: CAPP-Seq is applicable to clinical samples for the identification of multiple somatic mutations.The T790M mutation of <i>EGFR</i> is associated with amplification of <i>MET</i>, <i>ERBB2</i>, or <i>EGFR</i> in NSCLC patients resistant to EGFR-TKIs.T790M-positive patients are molecularly heterogeneous, and genetic alterations coexisting with T790M may differ between patients treated with first-generation or second-generation EGFR-TKIs.
|
31023862 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study.
|
31442277 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib (AZD9291), a third-generation EGFR-tyrosine kinase inhibitor, can effectively prolong survival in non-small cell lung cancer (NSCLC) patients with EGFR mutations, particularly T790M mutations; however, acquired resistance to AZD9291 is inevitable, thus exploration of the targets of resistance is urgent.
|
30883029 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two major mechanisms involved in resistant NSCLC (non-small cell lung cancer) include secondary acquired mutation in EGFR (epidermal growth factor receptor), that is, EGFR T790M and amplification of c-MET (hepatocyte growth factor receptor).
|
30047303 |
2019 |
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib is an irreversible EGFR inhibitor registered for advanced NSCLC patients whose tumors harbor recurrent somatic activating mutations in EGFR (EGFRm<sup>+</sup>) or the frequently occurring EGFR-T790M resistance mutation.
|
31175939 |
2019 |